BIOCENTRIQ
BioCentriq is the cell and gene therapy development and manufacturing center.
BIOCENTRIQ
Industry:
Biotechnology Genetics Manufacturing
Founded:
2019-01-01
Address:
Newark, New Jersey, United States
Country:
United States
Website Url:
http://www.biocentriq.com
Total Employee:
51+
Status:
Active
Contact:
973-642-7999
Similar Organizations
apceth Biopharma
apceth Biopharma is a GMP contract development and manufacturing organization.
Current Employees Featured
Official Site Inspections
http://www.biocentriq.com Semrush global rank: 5.66 M Semrush visits lastest month: 1.49 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BioCentriq" on Search Engine
Cell Therapy CDMO - About BioCentriq
BioCentriq is a global cell therapy Contract Development and Manufacturing Organization (CDMO) with a proven track record successfully transferring, developing, and manufacturing GMP drug …See details»
BioCentriq - Crunchbase Company Profile & Funding
BioCentriq is a cell and gene therapy development and manufacturing center. Acquired by. Green Cross Holding. Newark, New Jersey, United States. 101-250. Series A. Private. biocentriq.com. 10,184. Highlights. Total Funding Amount. Unlock for free. Contacts 46. Employee Profiles 2. Investors 1. Similar Companies 10. Company Insights. Powered by AI.See details»
BioCentriq® Announces the Successful Completion of $29.2M …
NEWARK, N.J., Jan. 3, 2024 /PRNewswire/ -- BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the successful completion of...See details»
BioCentriq in 2022 - BioCentriq
BioCentriq in 2022 - BioCentriq. A Message from CEO and Founder Haro Hartounian, Ph.D. 2022 has already been a year packed with growth and advancement, fueled by the need for regenerative medicine and the …See details»
BioCentriq® Announces the Successful Completion of $29.2M
NEWARK, N.J., Jan. 3, 2024 /PRNewswire/ -- BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the successful completion of its latest round of fundraising, securing $29.2M in …See details»
BioCentriq secures $29.2M investment to accelerate cell therapy ...
January 3, 2024. BioCentriq, a Newark-based cell-based therapy contract development and manufacturing organization, raised $29.2 million in Series A funding, according to a Wednesday announcement. The backers were not disclosed. The company intends to use the funds to enhance its facilities, invest in advanced technologies and expand its team.See details»
BioCentriq® Announces the Successful Completion of $29.2M …
NEWARK, N.J., Jan. 3, 2024 /PRNewswire/ -- BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the successful completion of...See details»
BioCentriq to Unveil LEAP™ Advanced Therapy Platform During …
NEWARK, N.J., May 24, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy announced today that CEO of...See details»
BioCentriq® Launches LEAPâ„¢ Advanced Therapy …
NEWARK, N.J., June 1, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAPâ„¢ Advanced...See details»
ABOUT BIOCENTRIQ - outsourcedpharma.com
BioCentriq is a global cell therapy Contract Development and Manufacturing Organization (CDMO) successfully developing, manufacturing, and releasing GMP drug product for use in clinical trials since 2022.See details»
BioCentriq® Expands its Executive Leadership Team with …
PR Newswire. Tue, Oct 3, 2023, 8:45 AM 3 min read. NEWARK, N.J., Oct. 3, 2023 /PRNewswire/ -- BioCentriq, a cell therapy CDMO (contract development and manufacturing organization), announced...See details»
BioCentriq - Cell and Gene
ABOUT BIOCENTRIQ. BioCentriq is a global cell therapy Contract Development and Manufacturing Organization (CDMO) successfully developing, manufacturing, and releasing GMP drug product for use in clinical trials since 2022.See details»
BioCentriq® Strengthens Cell Therapy CDMO Services with …
January 7, 2024 By Cade Hildreth (CEO) Leave a Comment. NEWARK, N.J. , — BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the successful completion of its latest round of fundraising, securing $29.2M in capital investment.See details»
Insights on Cell Therapy Manufacturing - BioCentriq
NEWARK, NJ, October 3, 2023 – BioCentriq, a cell therapy CDMO (contract development and manufacturing organization), announced today the appointment of Jennifer Manning, MPA, as its Chief Commercial Officer, effective October 3, 2023. “We are … Read more. Watch inar On-Demand: The Role of Platform Processes in Cell Therapy.See details»
BioCentriq® and Kytopen® Expand Partnership to Expedite …
NEWARK, N.J., June 6, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy announced today that it has...See details»
GC Signs Definitive Agreement to Acquire US CDMO BioCentriq, …
Apr 19, 2022 Founded in 2019 as a New Jersey Innovation Institute company, BioCentriq is well-positioned in the potentially $ 40 billion addressable market, end-to-end CDMO for cell and gene therapy process...See details»
Cytiva and BioCentriq awarded NIIMBL funding to accelerate …
Jun 27, 2023 Visit www.biocentriq.com to learn more. Cytiva and BioCentriq, a New Jersey based cell and gene therapy contract development and manufacturing organization (CDMO), have been awarded funding from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership whose mission …See details»
BioCentriq - A Cell Therapy CDMO with a Collaborative Approach
BioCentriq is a Cell Therapy CDMO with a highly collaborative approach. Learn how we prioritize transparency, quality and compliance.See details»
Autolomous and BioCentriq Partner to Speed Up Cell Therapy …
Apr 24, 2024 With industry-recognized leadership, scientists, engineers, analysts, and manufacturing specialists, along with established quality systems and modern infrastructure, BioCentriq is a trusted...See details»
BioCentriq - Funding, Financials, Valuation & Investors
$29.2M. in funding over 2 rounds. Their latest funding was raised on Jan 3, 2024 from a Series A round. BioCentriq is funded by National Institute for Innovation in Manufacturing Biopharmaceuticals. Unlock for free. Funding Rounds. Number of Funding Rounds 2. Total Funding Amount. Unlock for free. BioCentriq has raised a total of. $29.2M.See details»